{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:02:05Z","timestamp":1775584925852,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejmech.2023.115614","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T11:11:15Z","timestamp":1688209875000},"page":"115614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists"],"prefix":"10.1016","volume":"258","author":[{"given":"Wenxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixin","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanqiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianru","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruojing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yisi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haolong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-9700","authenticated-orcid":false,"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115614_bib1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2023.115614_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115614_bib3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115614_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"5","author":"Quek","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejmech.2023.115614_bib5","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111S","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2023.115614_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112311","article-title":"Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment","volume":"197","author":"Yang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib7","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-Ethyl-Chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115614_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"FXR is a molecular target for the effects of vertical sleeve gastrectomy","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115614_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature13135","article-title":"F. B?ckhed, FXR is a molecular target for the effects of vertical sleeve gastrectomy","volume":"509","author":"Ryan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115614_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"Xu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2023.115614_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155264","article-title":"Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: an overview and current perspectives","volume":"134","author":"Yan","year":"2022","journal-title":"Metab., Clin. Exp."},{"key":"10.1016\/j.ejmech.2023.115614_bib13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejmech.2023.115614_bib14","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115614_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/acsmedchemlett.8b00423","article-title":"Novel isoxazole derivatives with potent FXR agonistic activity prevent acetaminophen-induced liver injury","volume":"10","author":"Sepe","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115614_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14728214.2020.1796968","article-title":"Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists","volume":"25","author":"Shah","year":"2020","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2023.115614_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective Farnesoid X Receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115614_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115614_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115614_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115614_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tips.2009.08.001","article-title":"Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders","volume":"30","author":"Fiorucci","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115614_bib22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ejmech.2023.115614_bib23","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2004.07.007","article-title":"T0901317 is a dual LXR\/FXR agonist","volume":"83","author":"Houck","year":"2004","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejmech.2023.115614_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib26","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1016\/j.bmcl.2008.06.073","article-title":"Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064","volume":"18","author":"Akwabi-Ameyaw","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115614_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115614_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bioorg.2018.01.039","article-title":"Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold","volume":"77","author":"Li","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103209","article-title":"Discovery of HWL-088: a highly potent FFA1\/GPR40 agonist bearing a phenoxyacetic acid scaffold","volume":"92","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115574","article-title":"Discovery of novel potent GPR40 agonists containing imidazo 1,2-a pyridine core as antidiabetic agents","volume":"28","author":"Ye","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/jm058056x","article-title":"Substituted 2-(4-aminomethyl)phenoxy-2-methylpropionic acid PPAR alpha agonists. 1. Discovery of a novel series of potent HDLc raising agents","volume":"50","author":"Sierra","year":"2007","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115614_bib32","first-page":"1675","article-title":"Synthesis, characterization and antimicrobial evaluation of organozirconium (IV) complexes with 5-aminotetrazole Schiff bases","volume":"8","author":"Upadhyay","year":"2019","journal-title":"J. Appl. Chem."},{"key":"10.1016\/j.ejmech.2023.115614_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423005809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423005809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:00:25Z","timestamp":1759330825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423005809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"alternative-id":["S0223523423005809"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115614","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological studies of novel sulfonamide derivatives as farnesoid X receptor agonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115614"}}